Algorae Pharmaceuticals Limited has released a press release.
NTCELL and Parkinsons trial update
Filed with ASX ·
6ix hasn’t read this filing yet.
Algorae Pharmaceuticals Limited on 6ix
Story so far
Earlier from Algorae Pharmaceuticals
- LCT Strategy Update
- LCT to sell JV Shares and receive DIABECELL licence
- Appendix 4C - Quarterly
- Results of LCT Parkinsons trial require further analysis
- LCT files pericyte protective agent provisional patent
Later from Algorae Pharmaceuticals
- Preliminary Final Report and 2018 Financial Statements
- NTCELL Parkinsons trial patient data at 18 months
- NTCELL Parkinsons trial patient data 2 years after implant
- Preliminary Final Report and 2019 Financial Statements
- LCT to benefit from Semma Therapeutics acquisition by Vertex
Follow Algorae Pharmaceuticals into a list and get an email when it puts out news.
Follow Algorae Pharmaceuticals